Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter

Singh, Bramah N.; Connolly, Stuart J.; Roy, Denis; Kowey, Peter R.; Capucci, Alessandro; Radzik, David; Aliot, Étienne; Hohnloser, Stefan H.

doi:10.1056/nejmoa054686

Cited by 577 publications

(490 citation statements)

References 35 publications

Supporting

Mentioning

441

Contrasting

Unclassified

Order By: Relevance

“…Leki antyarytmiczne powodują w przybliżeniu podwojenie częstości utrzymywania rytmu zatokowego w porównaniu z placebo [580][581][582][583][584]. Gdy leki antyarytmiczne zawiodą, często skuteczna jest ablacja przezcewnikowa lub leczenie skojarzone [226,[585][586][587].…”

Section: Leczenie W Celu Kontroli Rytmu Serca U Pacjentów Z Migotanieunclassified

“…Dronedaron utrzymywał rytm zatokowy, zmniejszał częstość rytmu komór oraz zapobiegał hospitalizacjom z przyczyn sercowo-naczyniowych (głównie z powodu AF) oraz zgonom z przyczyn sercowo-naczyniowych u pacjentów z napadowym lub przetrwałym AF bądź trzepotaniem przedsionków, u których występowała co najmniej jedna odpowiednia współistniejąca choroba układu sercowo-naczyniowego [583,588,656]. Lek ten zwiększa umieralność wśród pacjentów po niedawnej dekompensacji niewydolności serca (z AF lub bez AF) [657], a także u pacjentów z utrwalonym AF, u których nie nastąpił powrót rytmu zatokowego [658].…”

Section: Dronedaronunclassified

See 1 more Smart Citation

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,331

4,193

View full text Add to dashboard Cite

Section: Leczenie W Celu Kontroli Rytmu Serca U Pacjentów Z Migotanieunclassified

Section: Dronedaronunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,331

4,193

View full text Add to dashboard Cite

“…These results are consistent with the results of a recent study on the effectiveness of dronedarone in treating persistent AF. 38 If amiodarone has no adverse mortality effect and is effective in achieving sinus rhythm, it may be a viable treatment option for patients who have uncontrollable symptoms of AF.…”

Section: Discussionmentioning

confidence: 99%

Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis

Doyle

2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

OBJECTIVE:To assess whether amiodarone, as part of a strategy to achieve sinus rhythm, is safe and effective compared with a placebo or rate control drug in patients with persistent atrial fibrillation (AF) of more than 30 days' duration. METHODS:Randomized controlled trials comparing amiodarone with a placebo or rate control drug were identified through the EMBASE (January 1, 1988, to October 18, 2008, MEDLINE (January 1, 1966, to October 18, 2008, and Cochrane Controlled Trials Register (second issue 2008) databases with no language restrictions. RESULTS:Twelve randomized controlled trials that involved a total of 5060 patients with persistent AF were considered. Amiodarone was more effective than a placebo or rate control drug in achieving sinus rhythm (21.3 vs 9.2 per 100 patient-years in sinus rhythm; relative risk [RR], 3.2; 95% confidence interval [CI], 1.9-5.5), and its use was not associated with an increased risk of long-term mortality (4.7 vs 3.9 per 100 patient-years; RR, 0.95; 95% CI, 0.8-1

show abstract

“…15 Subsequently, 2 multicenter, double-blind, randomized trials, the American-Australian Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADO-NIS) and the European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm (EURIDIS), assessed the efficacy of dronedarone, 400 mg twice daily, in patients with recurrent AF after cardioversion. 16 In both trials, treatment with dronedarone significantly delayed recurrence of AF compared with placebo with no major side effects. 17 Dronedarone also decreases the ventricular rate in patients who relapsed into AF, and this was confirmed in the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) trial.…”

Section: Antiarrhythmic Drugs For Treatment Of Atrial Fibrillationmentioning

confidence: 95%

Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation

Viles-González

Fuster

Halperin

et al. 2011

Clinical Cardiology

View full text Add to dashboard Cite

Antiarrhythmic drug (AAD) therapy may be beneficial for patients with symptoms attributable to atrial fibrillation despite adequate rate control. The limited long-term efficacy of AAD and the relatively large proportion of patients discontinuing therapy because of side effects led to the development of nonpharmacological therapies to achieve rhythm control. Pressing questions remain about the effect of ablation therapy on long-term patient outcomes. Based on recent clinical trials and meta-analyses, ablation appears more effective and possibly safer than AAD for long-term maintenance of sinus rhythm in selected patients, but the evidence is insufficient to recommend ablation in preference to drug therapy as the first AAD therapy for the majority of patients in whom a rhythm control strategy is justified. Herein, we review the most current evidence supporting the use of AAD and catheter ablation in atrial fibrillation.

show abstract

Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter

Abstract: Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.

Cited by 577 publications

References 35 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis

Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation

Contact Info

Product

Resources

About